Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,
"They're not shortcuts": How weight loss drugs became the business of shame
The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose medical interventions for weight management. Some critics argue that using the drugs is akin to "taking a shortcut," overlooking the complex factors that contribute to obesity.
Novel drug confers weight loss of up to 20% at 1 year in phase 2 study
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau,
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Lilly forecasts weak sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down 8% on Tuesday.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
New weight loss pill to be approved by early 2026: Eli Lilly
The weight loss pill aims to compete with popular injectable treatments like Eli Lilly's own Zepbound and Novo Nordisk's Wegovy, which currently dominate the space. If approved, orforglipron would offer a pill alternative to the current injectables,
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...
Hosted on MSN2d
Lilly forecasts weak sales of weight-loss drug in fourth quarter
(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to ...
WGBH8d
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
NOLA.com2d
Can weight loss drugs curb alcohol addictions? New research looks at the possibility.
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
Medscape2d
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
valuepenguin2d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
Insurance is more likely to cover weight loss drugs if they're prescribed for diabetes, not for weight loss. And your insurance company will usually need to preapprove the prescription and ...